Bio-Techne recently announced a licensing agreement with Monod Bio, granting it exclusive commercial rights to a subset of AI-designed NovoBody™ Duo molecules for use in research and next-generation ...
Narrow-moat Bio-Techne’s fourth-quarter earnings were in line with our expectations. Revenue was $306 million for the three months and $1.2 billion for the full year ended June 30, which both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results